Please login to the form below

Not currently logged in
Email:
Password:

medicines

This page shows the latest medicines news and features for those working in and with pharma, biotech and healthcare.

Time running out for ‘no-deal’ Brexit medicines laws

Time running out for ‘no-deal’ Brexit medicines laws

The UK’s medicine regulator issued its plans for a no deal Brexit last week, saying it has drawn up a “robust plan to make sure [the UK’s] regulatory processes ... for medicines, clinical trials and medical devices are fit for purpose on exit day”

Latest news

  • Blackwood returns as new life sciences minister Blackwood returns as new life sciences minister

    Replaces James O’Shaughnessy at DHSC. Nicola Blackwood has been appointed as the new minister at the Department of Health and Social Care (DHSC) overseeing the life sciences sector, medicines and

  • Gradually, then suddenly Gradually, then suddenly

    Company extinction is the result of cognitive shortcomings

  • EMA sees approval numbers rise in 2018 EMA sees approval numbers rise in 2018

    Agency faces Brexit test in 2019. The European Medicine Agency has revealed a final tally of 84 positive opinions on new medicines in 2018, with 42 of these being new active ... Lastly, the EMA’s key human medicines committee, the CHMP, has a new

  • NICE rejects Novartis migraine treatment Aimovig NICE rejects Novartis migraine treatment Aimovig

    Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.

  • NHS Long-term Plan welcomed – but warnings on staff and overpromising NHS Long-term Plan welcomed – but warnings on staff and overpromising

    UK pharma industry response. The new Long-term Plan coincides with the launch of a new five year Voluntary Pricing and Access Scheme (VPAS) covering branded medicines in the UK. ... There isn’t much mention of medicines in the Plan and where they fit

More from news
Approximately 138 fully matching, plus 3,501 partially matching documents found.

Latest Intelligence

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of non-cancer medicines to be in line with cancer medicine appraisals – cost-effective new medicines ... a medicine is no longer economic to supply

  • Launch excellence: beyond the six-month mantra Launch excellence: beyond the six-month mantra

    Individualised medicine, real-world evidence and algorithmic prescribing are emerging challenges and opportunities that launch teams need to address – how each company responds to these depends on its own unique context,

  • Escaping the spin cycle of sub-optimal launch Escaping the spin cycle of sub-optimal launch

    launching new medicines – confirms that the killer ingredients of launch excellence are impossible to isolate. ... Growing demand for real-world evidence and the drive towards individualised medicines are bringing new considerations to launch

  • Is China ready for a pharmaceutical gold rush?

    On top of that, several local firms including Junshi Biosciences, Innovent Biologics and Hengrui Medicine, are developing their own PD-1 I-O treatments that are expected to hit the market

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    PME. She is focused on scientific rigour and quality, with a passion for getting things done to ultimately deliver life-changing medicines for cancer patients. ... AstraZeneca is collaborating with numerous firms in this field, including Foundation

More from intelligence
Approximately 18 fully matching, plus 447 partially matching documents found.

Latest appointments

More from appointments
Approximately 10 fully matching, plus 341 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 18 fully matching, plus 254 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics